
Daraxonrasib plus gemcitabine/nab-paclitaxel yielded a 60.7% ORR and 12.8-month median PFS in first-line metastatic pancreatic adenocarcinoma.
Experts highlight key RCC studies at the 2026 Genitourinary Cancers Symposium, with a focus on combination-based strategies and patient-reported outcomes.
As anticipation builds for the






